High-dose GH treatment limited to the prepubertal period in young children with idiopathic short stature does not increase adult height
| Autor: | J.M. Wit, R. J. Odink, H.A. Delemarre-van de Waal, Gerdine A Kamp, S. van Gool, W. Oostdijk, S.M.P.F. de Muinck Keizer-Schrama |
|---|---|
| Přispěvatelé: | Pediatrics |
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty Endocrinology Diabetes and Metabolism Body Mass Index law.invention Young Adult Endocrinology Randomized controlled trial law Internal medicine Prepuberty medicine Humans Young adult Child Netherlands Bone Development Human Growth Hormone business.industry Puberty General Medicine medicine.disease Body Height Discontinuation Idiopathic short stature El Niño Child Preschool Linear Models Bone maturation growth-hormone deficiency final height pubertal growth age netherlands therapy onset born Female business Body mass index Follow-Up Studies |
| Zdroj: | European Journal of Endocrinology, 162(4), 653-660 European Journal of Endocrinology, 162, 653-660. Bioscientifica Ltd |
| ISSN: | 1479-683X 0804-4643 |
| Popis: | ObjectiveTo assess the long-term effect of prepubertal high-dose GH treatment on growth in children with idiopathic short stature (ISS).Design and methodsForty children with no signs of puberty, age at start 4–8 years (girls) or 4–10 years (boys), height SDS −2.0 SDS, were randomly allocated to receive GH at a dose of 2 mg/m2 per day (equivalent to 75 μg/kg per day at start and 64 μg/kg per day at stop) until the onset of puberty for at least 2 years (preceded by two 3-month periods of treatment with low or intermediate doses of GH separated by two washout periods of 3 months) or no treatment. In 28 cases, adult height (AH) was assessed at a mean (s.d.) age of 20.4 (2.3) years.ResultsGH-treated children (mean treatment period on high-dose GH 2.3 years (range 1.2–5.0 years)) showed an increased mean height SDS at discontinuation of the treatment compared with the controls (−1.3 (0.8) SDS versus −2.6 (0.8) SDS respectively). However, bone maturation was significantly accelerated in the GH-treated group compared with the controls (1.6 (0.4) versus 1.0 (0.2) years per year, respectively), and pubertal onset tended to advance. After an untreated interval of 3–12 years, AH was −2.1 (0.7) and −1.9 (0.6) in the GH-treated and control groups respectively. Age was a positive predictor of adult height gain.ConclusionHigh-dose GH treatment restricted to the prepubertal period in young ISS children augments height gain during treatment, but accelerates bone maturation, resulting in a similar adult height compared with the untreated controls. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|